Segall Bryant & Hamill LLC Decreases Stake in Pediatrix Medical Group, Inc. (NYSE:MD)

Segall Bryant & Hamill LLC decreased its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 5.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,244,950 shares of the company's stock after selling 74,289 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 1.45% of Pediatrix Medical Group worth $14,429,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MD. Rubric Capital Management LP increased its position in Pediatrix Medical Group by 797.0% during the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company's stock worth $61,532,000 after buying an additional 7,241,400 shares during the period. Dana Investment Advisors Inc. raised its position in Pediatrix Medical Group by 80.3% in the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company's stock valued at $7,725,000 after purchasing an additional 455,785 shares during the last quarter. Boston Partners boosted its stake in Pediatrix Medical Group by 34.0% during the 1st quarter. Boston Partners now owns 1,786,434 shares of the company's stock worth $17,702,000 after purchasing an additional 453,254 shares during the period. Cubist Systematic Strategies LLC grew its position in Pediatrix Medical Group by 639.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company's stock worth $2,192,000 after purchasing an additional 251,072 shares during the last quarter. Finally, ClariVest Asset Management LLC acquired a new position in Pediatrix Medical Group in the second quarter valued at $1,721,000. 97.71% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Pediatrix Medical Group

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the firm's stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the sale, the executive vice president now owns 135,810 shares in the company, valued at $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mark S. Ordan sold 27,600 shares of the company's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the transaction, the director now owns 138,683 shares of the company's stock, valued at $2,128,784.05. The trade was a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 53,808 shares of company stock valued at $751,277. 2.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on MD. Truist Financial raised their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a "hold" rating in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft lifted their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a "hold" rating in a research note on Monday, November 4th. Jefferies Financial Group upped their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Mizuho lifted their price objective on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a "neutral" rating in a research report on Tuesday. Finally, UBS Group lifted their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Pediatrix Medical Group presently has an average rating of "Hold" and a consensus price target of $16.10.

Pediatrix Medical Group Price Performance

Shares of MD traded up $0.26 during trading hours on Thursday, reaching $14.75. The company had a trading volume of 531,265 shares, compared to its average volume of 864,097. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83. Pediatrix Medical Group, Inc. has a 12-month low of $6.62 and a 12-month high of $16.41. The firm has a 50 day simple moving average of $12.84 and a 200-day simple moving average of $10.00. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of -4.82, a PEG ratio of 2.08 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. During the same period in the previous year, the business earned $0.29 earnings per share. Pediatrix Medical Group's quarterly revenue was up .9% compared to the same quarter last year. Research analysts expect that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.